In conclusion, the increase in TL under treatment with TKI reflects a shift from Ph+ to Ph− cells in patients with CML, thereby reflecting response to TKI treatment and the comeback of normal (BCR-ABL negative) polyclonal hematopoiesis [24]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.